A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients With Inhibitors

Trial Profile

A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients With Inhibitors

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Emicizumab (Primary)
  • Indications Haemophilia A
  • Focus Registrational; Therapeutic Use
  • Acronyms HAVEN 1
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 12 Dec 2017 Results describing combined surgical experiences from HAVEN 1 and HAVEN 2 studies, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results describing treatment of breakthrough bleeds prior to and following bypassing agents dosing during emicizumab prophylaxis, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Updated results (n=112; As of April 21, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top